497159-91-8 Usage
Uses
Used in Pharmaceutical Industry:
DI-TERT-BUTYL [5-BROMO-3-METHYLPYRIDIN-2-YL]IMIDODICARBONATE is used as an intermediate in the synthesis of pharmaceuticals. Its role in this industry is crucial for the production of various medications, contributing to the development of new drugs and the improvement of existing ones.
Used in Agrochemical Industry:
Similarly, in the agrochemical sector, DI-TERT-BUTYL [5-BROMO-3-METHYLPYRIDIN-2-YL]IMIDODICARBONATE serves as an intermediate in the synthesis of various agrochemicals. It plays a significant part in the creation of products that protect crops and enhance agricultural productivity, thereby supporting food security and sustainable agriculture practices.
Check Digit Verification of cas no
The CAS Registry Mumber 497159-91-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,9,7,1,5 and 9 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 497159-91:
(8*4)+(7*9)+(6*7)+(5*1)+(4*5)+(3*9)+(2*9)+(1*1)=208
208 % 10 = 8
So 497159-91-8 is a valid CAS Registry Number.
497159-91-8Relevant academic research and scientific papers
INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS
-
Page/Page column 75, (2011/06/25)
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa)
Polla, Magnus O.,Tottie, Louise,Norden, Carita,Linschoten, Marcel,Muesil, Djordje,Trumpp-Kallmeyer, Susanne,Aukrust, Inger R.,Ringom, Rune,Holm, Kjetil H.,Neset, Siren M.,Sandberg, Marcel,Thurmond, John,Yu, Peng,Hategan, Georgeta,Anderson, Herb
, p. 1151 - 1175 (2007/10/03)
A series of 3-mercapto-propionic acid derivatives that function as reversible inhibitors of carboxypeptidase U have been prepared. We present a successful design strategy using cyclic, low basicity guanidine mimetics resulting in potent, selective and bioavailable inhibitors of carboxypeptidase U (TAFIa).
